We have been very bullish on Biovica. I wrote here several times about the opportunity, I published articles on SumZero and SeekingAlpha. We viewed the likelihood of the FDA approval for its Breast Cancer Test as over 90%. Market gave it much lower probability, the not patient retail sold the stock. Biovica got their FDA approval about two weeks ago. The company is now preparing its US and European market lunch. We are bullish Biovica
Biovica invites to market update on 18 August 15.00 – Bringing DiviTum®TKa to US patients
Biovica, active in cancer diagnostics, is hosting a market update due DiviTum®TKa’s US market approval received on July 29 from the US Food and Drug Administration (FDA).
At the update on Thursday 18 August 15.00-16.00 CET, CEO Anders Rylander will give a short introduction. Joakim Arwidsson, VP RA/QA, about the 510(k) clearance, Henrik Winter, SVP Business Development, will describe the clinical application of the test and Warren Cresswell, President Americas, will describe the US Go-to-market plan.
DiviTum®TKa received 510(k) clearance on July 29, 2022, as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients.
Link to the event: Biovica International Market update FDA clearance 2022 (streamfabriken.com)
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice. Please do your own research before making any investment action.